Brief: Selectimmune Pharma Signs Deal On Phase II Study For Infection Treatment
29/10/2020 08:58
Oct 29 (Reuters) - Selectimmune Pharma AB SELECTb.TE :
* SIGNS DEAL ON PHASE II STUDY FOR INFECTION TREATMENT
* STUDY TO BE CARRIED OUT IN GERMANY
Source text for Eikon: ID:nWkrbbrsGj
Further company coverage: SELECTb.TE
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))
Recent news on Selectimmune Pharma AB
See all newsBrief: Selectimmune Pharma Says Co's CEO Ann Gidner Will Leave Selectimmune Pharma
Brief: Lonza Collaborates With Selectimmune Collaborates To Develop Immunotherapeutic Drug Candidate
Brief: Selectimmune Pharma Q2 Pretax Loss Widens To SEK 3.1 Mln
Brief: Selectimmune Pharma Q1 Pretax Loss Narrows To SEK 2.2 Million
Brief: Selectimmune Pharma Signs Deal On Phase II Study For Infection Treatment